{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:47:22Z","timestamp":1764784042374,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s10620-018-4921-y","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T08:48:00Z","timestamp":1516265280000},"page":"746-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Anti-Tumor Necrosis Factor-\u03b1-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-0947","authenticated-orcid":false,"given":"P.","family":"Andrade","sequence":"first","affiliation":[]},{"given":"S.","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"R.","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"A.","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"S.","family":"Magina","sequence":"additional","affiliation":[]},{"given":"G.","family":"Macedo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"4921_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417\u2013429.","journal-title":"N Engl J Med"},{"key":"4921_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"4921_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"4921_CR4","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"4921_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","volume":"7","author":"G Mocci","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769\u2013779.","journal-title":"J Crohns Colitis"},{"key":"4921_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gut.2008.163683","volume":"58","author":"JF Kerbleski","year":"2009","unstructured":"Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut. 2009;58:1033\u20131039.","journal-title":"Gut"},{"key":"4921_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1556\/OH.2011.28987","volume":"152","author":"G Nagy","year":"2011","unstructured":"Nagy G, Luk\u00e0cs K, Sziray A, et al. Adverse events during biological therapy: focusing on dermatological side effects. Orv Hetil. 2011;152:212\u2013220.","journal-title":"Orv Hetil"},{"key":"4921_CR8","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666\u2013R676.","journal-title":"Arthritis Res Ther"},{"key":"4921_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee HH, Song IH, Friedrich M, et al. Cutaneous side effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486\u2013491.","journal-title":"Br J Dermatol"},{"key":"4921_CR10","first-page":"5:106","volume":"P223","author":"J Llao","year":"2011","unstructured":"Llao J, Gomez-Pastrana B, Gordillo J, et al. Skin lesions in patients with inflammatory bowel disease treated with immunomodulators and\/or anti-tumor necrosis factor. J Crohns Colitis. 2011;P223:5:106.","journal-title":"J Crohns Colitis"},{"key":"4921_CR11","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/MIB.0b013e3182802c07","volume":"19","author":"J Torres","year":"2013","unstructured":"Torres J, Buche S, Delaporte E, et al. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2013;19:1086\u20131098.","journal-title":"Inflamm Bowel Dis"},{"key":"4921_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"H Fidder","year":"2009","unstructured":"Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501\u2013508.","journal-title":"Gut"},{"key":"4921_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","volume":"8","author":"A Afzali","year":"2014","unstructured":"Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480\u2013488.","journal-title":"J Crohns Colitis"},{"key":"4921_CR14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"E Fr\u00e9ling","year":"2015","unstructured":"Fr\u00e9ling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186\u20131196.","journal-title":"Am J Gastroenterol"},{"key":"4921_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","volume":"20","author":"T M\u00e4lk\u00f6nen","year":"2014","unstructured":"M\u00e4lk\u00f6nen T, Wikstr\u00f6m A, Heiskanen K, et al. Skin reactions during anti-TNF\u03b1 therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20:1309\u20131315.","journal-title":"Inflamm Bowel Dis"},{"key":"4921_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","volume":"63","author":"C Tillack","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterized by interferon-\u03b3-expressing Th 1 cells and IL-17 A\/IL-22-expressing Th 17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut. 2014;63:567\u2013577.","journal-title":"Gut"},{"key":"4921_CR17","first-page":"1048","volume":"8","author":"J-F Rahier","year":"2010","unstructured":"Rahier J-F, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8:1048\u20131055.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"4921_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/MIB.0b013e3182802c93","volume":"19","author":"T Broge","year":"2013","unstructured":"Broge T, Nguyen N, Sacks A, et al. Infliximab-associated psoriasis in children with Crohn\u2019s disease may require withdrawal of anti-tumor necrosis factor therapy. Inflamm Bowel Dis. 2013;19:75\u201377.","journal-title":"Inflamm Bowel Dis"},{"key":"4921_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","volume":"40","author":"AN Collamer","year":"2010","unstructured":"Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233\u2013240.","journal-title":"Semin Arthritis Rheum"},{"key":"4921_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","volume":"9","author":"I Cleynen","year":"2012","unstructured":"Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496\u2013503.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4921_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M15-0729","volume":"5","author":"I Cleynen","year":"2016","unstructured":"Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;5:10\u201322.","journal-title":"Ann Intern Med"},{"key":"4921_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3109\/00365521.2015.1125524","volume":"51","author":"EA Hellstrom","year":"2016","unstructured":"Hellstrom EA, Farkkila M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:563\u2013571.","journal-title":"Scand J Gastroenterol"},{"key":"4921_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-4632.2011.05205.x","volume":"51","author":"A Ortiz","year":"2012","unstructured":"Ortiz A, Grando SA. Smoking and the skin. Int J Dermatol. 2012;51:250\u2013262.","journal-title":"Int J Dermatol"},{"key":"4921_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","volume":"6","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet L, Deltenre P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo controlled trials. Clin Gastroenterol Hepatol. 2008;6:644\u2013653.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4921_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"G Lichtenstein","year":"2006","unstructured":"Lichtenstein G, Feagan B, Cohen R, et al. Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621\u2013630.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4921_CR26","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403\u20133412.","journal-title":"Arthritis Rheum"},{"key":"4921_CR27","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368\u20132376.","journal-title":"Arthritis Rheum"},{"key":"4921_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","volume":"3","author":"JF Rahier","year":"2009","unstructured":"Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47\u201391.","journal-title":"J Crohns Colitis"},{"key":"4921_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929\u2013936.","journal-title":"Gastroenterology"},{"key":"4921_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","volume":"6","author":"I Guerra","year":"2012","unstructured":"Guerra I, Algaba A, P\u00e9rez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518\u2013523.","journal-title":"J Crohns Colitis"},{"key":"4921_CR31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","volume":"29","author":"G Fiorino","year":"2009","unstructured":"Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921\u2013927.","journal-title":"Aliment Pharmacol Ther"},{"key":"4921_CR32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","volume":"34","author":"G Cullen","year":"2011","unstructured":"Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318\u20131327.","journal-title":"Aliment Pharmacol Ther"},{"key":"4921_CR33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","volume":"22","author":"I Guerra","year":"2016","unstructured":"Guerra I, P\u00e9res-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22:894\u2013901.","journal-title":"Inflamm Bowel Dis"},{"key":"4921_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","volume":"7","author":"R Denadai","year":"2013","unstructured":"Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517\u2013524.","journal-title":"J Crohns Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-018-4921-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:00:58Z","timestamp":1659085258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-018-4921-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4921"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-4921-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2018,1,18]]},"assertion":[{"value":"21 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}